Lars Fruergaard Jørgensen CEO of Novo Nordisk
In Good Company with Nicolai Tangen
Navigating Drug Access and Innovation
This chapter examines the challenges of ensuring essential medications reach those in need while balancing profit and care. It contrasts the U.S. healthcare system's rapid innovation capabilities with the slower processes in Europe, emphasizing the importance of equitable access to medical advancements. Additionally, it discusses the broader implications of obesity treatments and the potential impact of regulatory changes on healthcare access in Europe.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
